FDA recall D-0984-2017

Teva Pharmaceuticals USA · Class III · drug

Product

Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg 30 tablets per Bottle, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5721-56

Reason for recall

Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.

Distribution

Nationwide in the USA

Key facts

Status
Terminated
Initiation date
2017-06-29
Report date
2017-07-26
Termination date
2018-04-26
Voluntary/Mandated
Voluntary: Firm initiated
Location
North Wales, PA, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0984-2017